Shruti Bhat PhD (Pharmaceutics), MBA, Lean Six Sigma Black Belt
  • Consulting
  • Case Studies
  • Workshops
  • Books
  • Hall of Fame
  • Learning Center
  • Patents
  • Publications
  • Contact

Update on Romidepsin Injection :

11/6/2009

0 Comments

 
Here is an update on drug product research from my reading –

On November 5, 2009, the U.S. Food and Drug Administration granted approval to romidepsin for injection (ISTODAX, Gloucester Pharmaceuticals Inc.) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.

The efficacy and safety of romidepsin were evaluated in two single-arm, multicenter, open label trials.  Efficacy was assessed in 167 patients with CTCL treated in the United States, Europe, and Australia. 

The recommended dose and schedule of romidepsin is 14 mg/m2 intravenously over 4 hours on days 1, 8 and 15 of a 28-day cycle. 
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

© Copyright 1992- 2019 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media